Biodexa Pharmaceuticals (BDRX) Income from Continuing Operations (2013 - 2025)
Biodexa Pharmaceuticals (BDRX) reported Income from Continuing Operations of 5297495.41 for Q2 2025, down 16.0% sequentially from 4566699.54 in Q4 2024.
Biodexa Pharmaceuticals (BDRX) Income from Continuing Operations (2013 - 2025) Analysis & Trends
Biodexa Pharmaceuticals (BDRX) has 12 years of Income from Continuing Operations data on file, last reported at 5297495.41 in Q2 2025.
- For the quarter ending Q2 2025, Income from Continuing Operations changed N/A year-over-year to 5297495.41; the trailing twelve-month figure through Jun 2025 stood at 23979473.14 (changed N/A YoY), and the FY2025 full-year result was 8694257.16, down 8.75% from the prior year.
- Income from Continuing Operations fell to 5297495.41 in Q2 2025, from 4566699.54 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 4566699.54 in Q4 2024 to a low of 10415603.49 in Q4 2022.
- A 5-year average of 6575200.48 and a median of 5167883.84 in 2021 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations jumped 78.13% in 2021 and dropped 21.83% in 2022, its largest moves.
- Tracing BDRX's Income from Continuing Operations over 5 years: stood at 8549083.27 in 2021, then dropped by 21.83% to 10415603.49 in 2022, then rose by 10.81% to 9290021.86 in 2023, then soared by 50.84% to 4566699.54 in 2024, then fell by 16.0% to 5297495.41 in 2025.
- Business Quant data shows BDRX's Income from Continuing Operations at 5297495.41 in Q2 2025, 4566699.54 in Q4 2024, and 9290021.86 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Biodexa Pharmaceuticals | 18.43 Bn | 18.43 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -5.30 Mn |
| Dec 31, 2024 | -4.57 Mn |
| Dec 31, 2023 | -9.29 Mn |
| Jun 30, 2023 | -4.83 Mn |
| Dec 31, 2022 | -10.42 Mn |
| Sep 14, 2022 | -4.62 Mn |
| Dec 31, 2021 | -8.55 Mn |
| Sep 17, 2021 | -5.04 Mn |
| Dec 31, 2020 | -31.78 Mn |
| Sep 10, 2020 | -23.04 Mn |
| Dec 31, 2019 | -15.11 Mn |
| Dec 31, 2018 | -18.57 Mn |
| Dec 31, 2016 | -15.37 Mn |
| Dec 31, 2015 | -44.50 Mn |
| Dec 31, 2014 | -15.59 Mn |
| Dec 31, 2013 | -7.91 Mn |